English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Th17 cells are abundant in multiple chronic inflammatory and autoimmune diseases. Clinical trials with antibodies to interleukin (IL)-17A, one of the Th17-cell signature cytokines, have recently reported therapeutic benefit in multiple patient populations; however, in Crohn's disease the role of Th17 cells and IL-17A appears to be more complicated. The development of different subsets of Th17 cells and their relative pathogenic activities with a focus on the gut environment will be discussed.

Are Th17 cells in the gut pathogenic or protective?